Clinical Trials Directory

Trials / Completed

CompletedNCT02885363

Prognosis of Isolated Left Ventricular Non-compaction in Adults

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
175 (actual)
Sponsor
Assistance Publique Hopitaux De Marseille · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The main objective of this study is to clarify prospectively prognosis of patients newly diagnosed as carriers of a LVNC (incident cases) (i.e. without the occurrence of a survival of the following events: death, heart transplantation or hospitalization for cardiovascular complications). In a second time, prognosis factors will be identify in these patients with LVNC.

Detailed description

Isolated Left Ventricular Non Compaction (LVNC) is a rare cause of cardiomyopathy supposed to result from the cessation of normal embryogenesis infarction, and characterized by persistent ventricular trabeculations prominent. This is frequently a familial disease, but for which genetic characterization is still incomplete, and then requires the identification of new genes is desirable. The prognosis of LVNC is uncertain, with a mortality rate reported in the literature ranging from 2 to 38%. Some series conclude that LVNC is a very severe heart disease, responsible for a high mortality, other that LVNC is frequently associated with a favorable prognosis. These series are however limited by the short duration of follow-up and the small number of patients included. Between 2004 and 2006, a French registry LVNC, included 105 cases. It was found out that the LVNC was associated with a high rate of complications such as outbreaks of severe heart failure, need for heart transplantation, severe rhythm disorders, and embolic events. The prognosis of LVNC in France appears as pejorative: 1. \- there is no evidence that prognosis is different from other forms of cardiomyopathies. 2. \- the results of this register can be skewed by the inclusion of incident and prevalent cases (statistical survival bias). Thus, a longer-term monitoring and the identification of relevant prognostic markers are imperative to better understand this rare disease and to improve the therapeutic management.

Conditions

Interventions

TypeNameDescription
OTHERClinical examination
OTHERBlood sample
PROCEDUREEchocardiography

Timeline

Start date
2011-12-21
Primary completion
2015-10-23
Completion
2023-04-12
First posted
2016-08-31
Last updated
2023-04-14

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02885363. Inclusion in this directory is not an endorsement.